Physician profile
David Cho
NPI 1073777819
$1,456.30
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2021: $11.92 · 2023: $117 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $191.19 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $148.05 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $129.23 | 2019-2023 | Farxiga |
| Puma Biotechnology, INC. | $122.40 | 2019 | |
| Haemonetics Corporation | $120.41 | 2024 | Teg6s Hemostasis System |
| Bayer Healthcare Pharmaceuticals INC. | $94.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $76.81 | 2019 | |
| Celgene Corporation | $60.08 | 2019 | |
| Amgen INC. | $57.31 | 2019 | |
| Genentech USA, INC. | $50.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $47.19 | 2019 | |
| Lilly USA, LLC | $46.29 | 2019 | |
| Emd Serono, INC. | $34.60 | 2019 | |
| Tersera Therapeutics LLC | $31.22 | 2019 | |
| Incyte Corporation | $31.21 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.13 | 2019 | |
| Exelixis INC. | $22.76 | 2019 | |
| Shionogi INC | $21.45 | 2019 | |
| Janssen Biotech, INC. | $17.37 | 2019 | |
| Abbott Laboratories | $17.08 | 2023 | Proclaim |
| Clovis Oncology, INC. | $15.99 | 2019 | |
| Seagen INC. | $15.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.94 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.